Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Feb 29, 2024 4:05pm EST

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Feb 14, 2024 7:30am EST

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Dec 21, 2023 8:00am EST

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Dec 14, 2023 4:15pm EST

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Oct 31, 2023 7:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Oct 25, 2023 7:30am EDT

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

Oct 17, 2023 8:00am EDT

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Sep 20, 2023 7:30am EDT

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

Sep 19, 2023 8:30am EDT

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Aug 31, 2023 10:55am EDT

Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split

1
2
3
4
5
6
7
8
9
10
...13